Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.19
Views: 664

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

Dr Scott Tagawa speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the results of a phase I/II study into the use of sacituzumab govitecan in patients with previously treated metastatic urothelial cancer.

Addressing the findings Dr Tagawa explains that, while you would normally expect a 10% response rate from use of a chemotherapy agent, sacituzumab govitecan produced an approximate 30% response rate.

He explains that this could be considered a proof of concept study due to its small pool of patients but that the phase II TROPHY U01 study has been launched with 100 evaluable patients.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation